Puma shares drop after breast-cancer drug marketing filing delayed
Puma Biotechnology Inc. shares fell in the extended session Monday after the biotech said it would delay filing a marketing application for a cancer drug after the Food and Drug Administration asked for changes in how study data was analyzed. Puma shares dropped 17% to $29.37 after hours. The company said it plans to file a marketing application with the FDA in mid-2016 for its breast-cancer drug neratinib, later than the first-quarter filing date originally planned.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.